Dilemma of antiviral treatment in coronavirus 2019
| Autor: | Hossam H Masoud |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Egyptian Journal of Chest Disease and Tuberculosis, Vol 70, Iss 5, Pp 4-6 (2021) |
| Druh dokumentu: | article |
| ISSN: | 0422-7638 2090-9950 |
| DOI: | 10.4103/ejcdt.ejcdt_2402_20 |
| Popis: | There are four classes of Coronaviruses designated as alpha, beta, gamma and delta. CoV-2 attacks the lower respiratory system to cause severe pneumonia, but it may also affect other organs leading to multiple organ failure. The choice for antiviral treatment for CoV-2 depends on the timing and the severity of the case. Although there is no antiviral designed specifically for treating corona virus, several agents are tried such as hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir, and Favipiravir. The mechanism of each drug is diacussed in detail below. In addition, ivermectin has started to emerge as a new candidate therapeutic against SARS-CoV-2/ COVID-19. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|